DEA Controlled Substance Prescription Rule Correction

Regs.gov: Drug Enforcement Administration

Published March 31st, 2026

Detected April 3rd, 2026

Summary

The Drug Enforcement Administration issued a correction to 21 CFR § 1306.07, fixing paragraph letter references in amendatory instruction 15 from '(e)' and '(f)' to '(g)' and '(h)'. This technical correction to the controlled substance prescribing rule affects entities regulated under DEA's multiple prescription provisions.

View original document View source feed page

What changed

The DEA corrected a typographical error in rule document C1-2026-02288 affecting 21 CFR § 1306.07 (Issuing multiple prescriptions for schedule II controlled substances). The correction changes paragraph references '(e)' and '(f)' to '(g)' and '(h)' in amendatory instruction 15. The underlying rule relates to DEA regulations governing how practitioners may issue multiple prescriptions for Schedule II controlled substances.

This correction does not impose new requirements on regulated entities. No compliance actions, filings, or operational changes are required as a result of this technical correction. Entities already subject to the underlying § 1306.07 requirements should ensure their procedures reflect the corrected paragraph references.

Source document (simplified)

Content

Correction

In rule document 2026-02288, beginning on page 5216 in the issue of Thursday, February 5, make the following correction:

§ 1306.07 [Corrected] Regulatory Text On page 5242, in the first column, in amendatory instruction 15, paragraphs “(e)” and “(f)” should read “(g)” and “(h)”.

[FR Doc. C1-2026-02288 Filed 3-31-26; 8:45 am] BILLING CODE 0099-10-D